Aldose reductase inhibitor increases doxorubicin-sensitivity of colon cancer cells and decreases cardiotoxicity

Mechanisms of drug resistance in colon cancer and its therapeutic strategies

(2016) Tao Hu et al.   WORLD JOURNAL OF GASTROENTEROLOGY

Emerging delivery systems to reduce doxorubicin cardiotoxicity and improve therapeutic index

(2015) Esther Tahover et al.   ANTI-CANCER DRUGS

Aldo-keto reductase 1C3 (AKR1C3) is associated with the doxorubicin resistance in human breast cancer via PTEN Loss

(2015) Ting Zhong et al.   BIOMEDICINE & PHARMACOTHERAPY

Redundancy: A Critical Obstacle to Improving Cancer Therapy

(2015) O. Lavi   CANCER RESEARCH

Cardiotoxicity of anticancer treatments

(2015) Michael S. Ewer et al.   Nature Reviews Cardiology

Serum biomarkers evaluation to predict chemotherapy-induced cardiotoxicity in breast cancer patients

(2015) Francesca De Iuliis et al.   TUMOR BIOLOGY

Aldose reductase inhibition suppresses azoxymethane-induced colonic premalignant lesions in C57BL/KsJ-db/db mice

(2014) Ashish Saxena et al.   CANCER LETTERS

ROS Function in Redox Signaling and Oxidative Stress

(2014) Michael Schieber et al.   CURRENT BIOLOGY

Deregulation of cell signaling in cancer

(2014) Filippo G. Giancotti   FEBS LETTERS

Prevention of Anthracycline-Induced Cardiotoxicity

(2014) Pimprapa Vejpongsa et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Gene signatures of drug resistance predict patient survival in colorectal cancer

(2014) Y Zheng et al.   PHARMACOGENOMICS JOURNAL

Mechanism-Based Engineering Against Anthracycline Cardiotoxicity

(2013) Thomas Force et al.   CIRCULATION

Aldose reductase inhibition suppresses colon cancer cell viability by modulating microRNA-21 mediated programmed cell death 4 (PDCD4) expression

(2013) Ashish Saxena et al.   EUROPEAN JOURNAL OF CANCER

Aldose reductase inhibition enhances TRAIL-induced human colon cancer cell apoptosis through AKT/FOXO3a-dependent upregulation of death receptors

(2013) Mohammad Shoeb et al.   FREE RADICAL BIOLOGY AND MEDICINE

The FLT3 Inhibitor Quizartinib Inhibits ABCG2 at Pharmacologically Relevant Concentrations, with Implications for Both Chemosensitization and Adverse Drug Interactions

(2013) Jasjeet Bhullar et al.   PLoS One

Cytokines as Mediators of Chemotherapy-Associated Cognitive Changes: Current Evidence, Limitations and Directions for Future Research

(2013) Yin Ting Cheung et al.   PLoS One

Aldose Reductase Inhibition Prevents Colon Cancer Growth by Restoring Phosphatase and Tensin Homolog Through Modulation of miR-21 and FOXO3a

(2012) Ashish Saxena et al.   ANTIOXIDANTS & REDOX SIGNALING

Role of aldo-keto reductases and other doxorubicin pharmacokinetic genes in doxorubicin resistance, DNA binding, and subcellular localization

(2012) Allan D Heibein et al.   BMC CANCER

Molecular Pathways: Regulation and Therapeutic Implications of Multidrug Resistance

(2012) K. G. Chen et al.   CLINICAL CANCER RESEARCH

Aldo–Keto Reductase 1B10 and Its Role in Proliferation Capacity of Drug-Resistant Cancers

(2012) Toshiyuki Matsunaga et al.   Frontiers in Pharmacology

Inhibition of aldose reductase prevents angiogenesis in vitro and in vivo

(2011) Ravinder Tammali et al.   ANGIOGENESIS

Endothelial vascular toxicity from chemotherapeutic agents: Preclinical evidence and clinical implications

(2011) Aspasia Soultati et al.   CANCER TREATMENT REVIEWS

Inhibition of aldose reductase prevents colon cancer metastasis

(2011) Ravinder Tammali et al.   CARCINOGENESIS

Aldose reductase inhibition suppresses oxidative stress-induced inflammatory disorders

(2011) Satish K. Srivastava et al.   CHEMICO-BIOLOGICAL INTERACTIONS

Aldose Reductase Inhibition Prevents Hypoxia-induced Increase in Hypoxia-inducible Factor-1α (HIF-1α) and Vascular Endothelial Growth Factor (VEGF) by Regulating 26 S Proteasome-mediated Protein Degradation in Human Colon Cancer Cells

(2011) Ravinder Tammali et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

AKR1B10 induces cell resistance to daunorubicin and idarubicin by reducing C13 ketonic group

(2011) Linlin Zhong et al.   TOXICOLOGY AND APPLIED PHARMACOLOGY

P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808

(2010) J. E. Kolitz et al.   BLOOD

Crosstalk of reactive oxygen species and NF-κB signaling

(2010) Michael J Morgan et al.   CELL RESEARCH

Reactive oxygen species in cancer

(2010) Geou-Yarh Liou et al.   FREE RADICAL RESEARCH

Inhibition of Aldose Reductase Prevents Growth Factor–Induced G1-S Phase Transition through the AKT/Phosphoinositide 3-Kinase/E2F-1 Pathway in Human Colon Cancer Cells

(2010) Kota V. Ramana et al.   MOLECULAR CANCER THERAPEUTICS

Reversal of ABC Drug Transporter-Mediated Multidrug Resistance in Cancer Cells: Evaluation of Current Strategies

(2010) Chung-Pu Wu et al.   Current Molecular Pharmacology

Colorectal Cancer Epidemiology: Incidence, Mortality, Survival, and Risk Factors

(2009) Fatima Haggar et al.   Clinics in Colon and Rectal Surgery

Redox Regulation of Multidrug Resistance in Cancer Chemotherapy: Molecular Mechanisms and Therapeutic Opportunities

(2008) Macus Tien Kuo   ANTIOXIDANTS & REDOX SIGNALING

Chemotherapeutic drugs and human tumor cells cytokine network

(2008) Vera Levina et al.   INTERNATIONAL JOURNAL OF CANCER

Inactivation of the anticancer drugs doxorubicin and oracin by aldo–keto reductase (AKR) 1C3

(2008) Romana Novotna et al.   TOXICOLOGY LETTERS